Impax Laboratories Company Profile (NASDAQ:IPXL)

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

Impax Laboratories, Inc. (NASDAQ:IPXL) issued its earnings results on Wednesday, May, 10th. The company reported $0.11 EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.01. The business earned $184.40 million during the quarter, compared to analyst estimates of $193.17 million. Impax Laboratories had a negative net margin of 71.50% and a positive return on equity of 7.71%. Impax Laboratories's quarterly revenue was down 18.2% on a year-over-year basis. During the same quarter last year, the company earned $0.43 earnings per share. View Impax Laboratories' Earnings History.

Impax Laboratories updated its FY17 earnings guidance on Wednesday, May, 10th. The company provided earnings per share guidance of $0.55-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.71.

13 brokerages have issued 12-month price targets for Impax Laboratories' stock. Their forecasts range from $10.00 to $30.00. On average, they anticipate Impax Laboratories' stock price to reach $19.69 in the next year. View Analyst Ratings for Impax Laboratories.

Here are some recent quotes from research analysts about Impax Laboratories stock:

• 1. According to Zacks Investment Research, "Impax’s Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. However, the epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. The company is also taking steps to reduce costs and improve efficiencies, which is estimated to save a total of $130 million by the end of 2019. However, the company’s 2017 earnings guidance is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to hurt revenues. Moreover, the company’s manufacturing facilities had been hampered by quality control issues since 2011 and an inspection had even delayed Rytary’s approval. Impax is also involved in a patent litigation regarding approval of generic version of Rytary. Estimates have been mostly stable ahead of the Q2 results. Impax does not have an impressive record of earnings surprises in the recent quarters." (7/24/2017)
• 2. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
• 3. Royal Bank Of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)
• 4. BMO Capital Markets analysts commented, "an opportunistic one for IPXL and could drive some upside to our Adrenaclick forecasts." (1/13/2017)

Impax Laboratories saw a drop in short interest in June. As of June 15th, there was short interest totalling 7,670,468 shares, a drop of 15.0% from the May 31st total of 9,029,063 shares. Based on an average daily trading volume, of 1,564,712 shares, the days-to-cover ratio is currently 4.9 days. Approximately 10.7% of the shares of the company are sold short.

Some companies that are related to Impax Laboratories include BTG plc (BTG), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Pacira Pharmaceuticals (PCRX), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), Corcept Therapeutics Incorporated (CORT), Innoviva (INVA), Amphastar Pharmaceuticals (AMPH), Lannett Company (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Teligent (TLGT), Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Tetraphase Pharmaceuticals (TTPH) and Corium International (CORI).

Impax Laboratories' management team includes the folowing people:

• Robert L. Burr, Independent Chairman of the Board
• Paul M. Bisaro, President, Chief Executive Officer, Director
• Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance
• Douglas S. Boothe, President - Generics Division
• Michael J. Nestor, President - Impax Specialty Pharmaceutical Division
• Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary
• Jeffrey D. Nornhold, Senior Vice President - Technical Operations
• J. Kevin Buchi, Director
• Janet S. Vergis, Director
• Leslie Z. Benet Ph.D., Independent Director

Impax Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include GW&K Investment Management LLC (1.05%), Aperio Group LLC (0.08%), Bank of Montreal Can (0.08%), Fox Run Management L.L.C. (0.05%), Louisiana State Employees Retirement System (0.04%) and Legato Capital Management LLC (0.03%). Company insiders that own Impax Laboratories stock include Leslie Z Benet, Mark A Schlossberg, Michael Markbreiter, Michael Nestor and Peter R Terreri. View Institutional Ownership Trends for Impax Laboratories.

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC and Capstone Asset Management Co.. Company insiders that have sold Impax Laboratories stock in the last year include Leslie Z Benet and Michael Nestor. View Insider Buying and Selling for Impax Laboratories.

Impax Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Aperio Group LLC, Legato Capital Management LLC, Appleton Partners Inc. MA, State of Alaska Department of Revenue and Bank of Montreal Can. View Insider Buying and Selling for Impax Laboratories.

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Impax Laboratories stock can currently be purchased for approximately $18.75.